Literature DB >> 11522006

Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations--a cooperative project of the European Antiphospholipid Forum.

A Tincani1, F Allegri, M Sanmarco, M Cinquini, M Taglietti, G Balestrieri, T Koike, K Ichikawa, P Meroni, M C Boffa.   

Abstract

Despite the widely recognized practical importance of anticardiolipin (aCL) ELISA, the reliability of this test has been recently discussed. In order to investigate this area on European scale, we sent to 30 experienced centers a questionnaire focusing on the diagnostic procedures applied to patients with antiphospholipid syndrome (APS) and on the detailed protocols used to perform aCL. Anticardiolipin ELISA was found to be the most frequently performed test in patients with suspected APS, but significant difference was shown among the various protocols. The cross-laboratory multiple examination of ten serum samples evaluated independently by the 24 centers pointed out the difficulty in getting comparable results. Therefore a "consensus" protocol was derived from the aCL methods giving the best performance. The materials and reagents necessary to perform the "consensus" method, including, as putative standards, one IgG and one IgM monoclonal antibody (HCAL and EY2C9) were distributed to 19 Centers. The results of one IgG and one IgM aCL high positive sera measured in serial dilutions were compared. A progressive decrease in the variability of the values obtained for a given sample appeared evident when all the laboratories used the same standard, in their own in-house ELISA and even more in the "consensus" ELISA. Our data show that aCL ELISA standardization is necessary in order to obtain comparable results in different laboratories.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11522006

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  15 in total

1.  APhL antibody ELISA as an alternative to anticardiolipin test for the diagnosis of antiphospholipid syndrome.

Authors:  Brenda B Suh-Lailam; Anndorie Cromar; K Wayne Davis; Anne E Tebo
Journal:  Int J Clin Exp Pathol       Date:  2012-03-25

2.  Role of anticardiolipin antibodies in the pathogenesis of prosthetic valve thrombosis: An observational study.

Authors:  A Ç Aykan; T Gökdeniz; M Kalçık; M A Astarcıoğlu; S Gündüz; S Karakoyun; M O Gürsoy; A E Oğuz; E Ertürk; B Çakal; Z Bayram; M Özkan
Journal:  Herz       Date:  2014-01-19       Impact factor: 1.443

3.  Autoimmune reactivity of IgM acquired after oxidation.

Authors:  Jasna Omersel; Ivica Avberšek-Lužnik; Pegi Ahlin Grabnar; Tanja Kveder; Blaž Rozman; Borut Božič
Journal:  Redox Rep       Date:  2011       Impact factor: 4.412

4.  Exploring Autoimmunity in a Cohort of Children with Genetically Confirmed Aicardi-Goutières Syndrome.

Authors:  Marco Cattalini; Jessica Galli; Laura Andreoli; Ivana Olivieri; Giada Ariaudo; Micaela Fredi; Simona Orcesi; Angela Tincani; Elisa Fazzi
Journal:  J Clin Immunol       Date:  2016-08-18       Impact factor: 8.317

5.  Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin.

Authors:  Romy M W Kremers; Stéphane Zuily; Hilde Kelchtermans; Tessa C Peters; Saartje Bloemen; Véronique Regnault; H Coenraad Hemker; Philip G de Groot; Denis Wahl; Bas de Laat
Journal:  Blood Adv       Date:  2018-06-12

6.  Antiphospholipid antibody profile-based outcome of purely vascular and purely obstetric antiphospholipid syndrome.

Authors:  Amihai Rottenstreich; Ariela Arad; Hadas Terespolsky; Uriel Elchalal; Hagai Amsalm; Batia Roth; Yosef Kalish
Journal:  J Thromb Thrombolysis       Date:  2018-08       Impact factor: 2.300

7.  Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures.

Authors:  F Scanzi; L Andreoli; M Martinelli; M Taraborelli; I Cavazzana; N Carabellese; R Ottaviani; F Allegri; F Franceschini; N Agmon-Levin; Y Shoenfeld; Angela Tincani
Journal:  Immunol Res       Date:  2017-02       Impact factor: 4.505

8.  Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.

Authors:  Fabiola Atzeni; Piercarlo Sarzi-Puttini; Donata Dell' Acqua; Simona de Portu; Germana Cecchini; Carola Cruini; Mario Carrabba; Pier Luigi Meroni
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

9.  Sequential induction of effector function, tissue migration and cell death during polyclonal activation of mouse regulatory T-cells.

Authors:  Daniela Langenhorst; Tea Gogishvili; Eliana Ribechini; Susanne Kneitz; Kirsty McPherson; Manfred B Lutz; Thomas Hünig
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

Review 10.  Antiphospholipid antibodies: paradigm in transition.

Authors:  Lawrence L Horstman; Wenche Jy; Carlos J Bidot; Yeon S Ahn; Roger E Kelley; Robert Zivadinov; Amir H Maghzi; Masoud Etemadifar; Seyed Ali Mousavi; Alireza Minagar
Journal:  J Neuroinflammation       Date:  2009-01-20       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.